top of page
スクリーンショット 2025-07-13 16.08.17.png

Director: Yoshihiko Suzuki, MD, Doctor

Diabetes specialist

phone

0120-954-833

Email

Address (access)

Atlas Building 1F, 5-3 Ichibancho, Chiyoda-ku

(2-3 minutes walk from Hanzomon Station)

Diabetes specialist. Numerous academic papers.

Graduated from Keio University School of Medicine. Over 100 books.

A brief self-introduction by Dr. Yoshihiko Suzuki

Educational background and early career

Dr. Yoshihiko Suzuki graduated from Keio University School of Medicine in 1983. After receiving his medical education at Keio University, one of the most prestigious medical schools in Japan, he worked at the Department of Internal Medicine at Tokyo Saiseikai Central Hospital, where he specialized in diabetes treatment. During this initial training period, he learned about the complexity of diabetes, a lifestyle-related disease, and the importance of medical care that is tailored to each individual patient, laying the foundation for his subsequent career as a doctor.

 

He holds a PhD in medicine and has established a solid foundation not only as a clinician but also as a researcher. He has been researching and treating diabetes for over 30 years, and the accumulated experience and knowledge over these many years has led to his current position as a leading expert.

 

Current activities and roles at medical institutions

Dr. Suzuki currently practices medicine as the director of HDC Atlas Clinic (Chiyoda-ku, Tokyo). The clinic provides high-level outpatient diabetes care by diabetes specialists, and is one of the leading specialist clinics in Japan, particularly in terms of prescribing Manjaro (tirzepatide), the latest diabetes treatment drug.

Manjaro is a GIP/GLP-1 receptor agonist that has revolutionized the treatment of type 2 diabetes, and is attracting attention for its potential to not only control blood sugar levels but also help with weight loss. The fact that Dr. Suzuki's clinic has the highest record in Japan for prescribing this new drug is proof that they are actively adopting the latest treatments and providing them to many patients.

 

Academic achievements and teaching activities

Dr. Suzuki served as a visiting professor at Nippon Medical School from 2004 to 2017, and has also devoted himself to nurturing the next generation of doctors. Through his educational activities over the past 13 years, he has imparted knowledge and techniques on diabetes treatment to many young doctors and medical students.

In terms of research, he has published 47 research papers, contributing to elucidating the pathology of diabetes and developing new treatments. These papers have been published in academic journals both in Japan and overseas, contributing to the advancement of diabetes research worldwide. He is also engaged in genetic research, continuing to explore the mechanisms of diabetes onset and the potential for personalized medicine.

 

Writing and contributions to society

One of Dr. Suzuki's most notable achievements is his extensive writing output. He has written over 100 books on topics such as diabetes treatment, diet, dietary therapy, and blood sugar management, some of which have sold millions of copies. These books play an important role in conveying specialized medical knowledge to the general public in an easy-to-understand manner.

Diabetes and obesity are diseases for which improving the patient's own lifestyle is key to treatment, so patient education is extremely important. Dr. Suzuki's book is a valuable source of information for patients and the general public to correctly understand diabetes and adopt appropriate lifestyle habits. The fact that it has sold over a million copies is proof that its content has been accepted by many people and is actually useful.

 

Social reputation and recognition

Dr. Suzuki is known as "one of the most renowned diabetes specialists in Tokyo," and his abilities have been objectively proven through various rankings and selections. In the "National Doctor Rankings," he has been ranked first in the diabetes clinic category and second in his field multiple times, earning him high praise from the medical community and patients alike.

He has also been selected as a "Best Doctor," a prestigious certification chosen by doctors through peer evaluation. This means that he has been recognized by his fellow doctors as "a doctor that you or your family would want to see if you were ill," demonstrating his high level of expertise and trustworthiness.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contributions and features in diabetes treatment

What is unique about Dr. Suzuki's diabetes treatment, obesity care, and diet medicine is his comprehensive approach, which combines the latest medical knowledge with many years of clinical experience.

Of particular note is his well-balanced approach to clinical practice, research, and patient education. While many physicians specialize in either clinical practice or research, Dr. Suzuki has achieved outstanding results in both fields while also actively engaging in educational activities for the general public. One example of this is the GLP1.com membership service, which will begin in July 2025.

 

This activity is possible because we recognize the need for a multifaceted approach, with a deep understanding of the characteristics of diabetes and obesity, a deep knowledge of diet medicine, and a thorough understanding of medical digital transformation.

Work experience

December 2018 - January 2025

April 2025 - July 2025

Online medical consultations and nationwide coverage: This service, which is becoming the industry standard and highly convenient for busy modern people and users living far away, was built on an existing online medical platform and allowed ample time for online consultations and aftercare, with each session lasting 20 minutes. The clinic was renowned for its high retention rate and customer satisfaction. In particular, the price of Saxenda was clear and inexpensive, and the service offered a one-stop service from consultation to medication delivery. It was highly rated for its nationwide coverage and the convenience of not requiring a visit to the clinic.

In addition to Saxenda, Zepbound was released on April 11th, and Zepbound 7.5mg became available for prescription from July. Manjaro, Ryversus, and Ozempic were not available at all because they were prescribed for other purposes, but the addition of Zepbound has enriched the lineup.

2025年7月〜

We started with the MyMedipro primary service, and after much trial and error, we launched the "GLP1.com Membership Service." We are currently adding new services to expand our service lineup and increase patient options. We are currently in the middle of this process.

bottom of page